Lyra Therapeutics, Inc. (LYRA)
OTCMKTS · Delayed Price · Currency is USD
0.2000
+0.1900 (1,900.00%)
At close: Aug 28, 2026
Lyra Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 15.89 | 40.58 | 22.35 | 32.55 | 45.75 |
Short-Term Investments | - | - | 80.4 | 65.34 | - |
Cash & Short-Term Investments | 15.89 | 40.58 | 102.75 | 97.89 | 45.75 |
Cash Growth | -60.83% | -60.51% | 4.96% | 113.99% | -38.67% |
Prepaid Expenses | 0.38 | 2.45 | 2.07 | 2.94 | 2.17 |
Total Current Assets | 16.27 | 43.03 | 104.82 | 100.83 | 47.92 |
Property, Plant & Equipment | 17.84 | 21.33 | 35.28 | 4.47 | 5.86 |
Other Long-Term Assets | 1.99 | 1.99 | 2.5 | 4.67 | 1.09 |
Total Assets | 36.11 | 66.35 | 142.6 | 109.97 | 54.87 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.66 | 1.18 | 3.13 | 2.62 | 3.13 |
Accrued Expenses | 0.26 | 2.11 | 8.14 | 8.37 | 3.63 |
Current Portion of Leases | 4.82 | 4.12 | 5.43 | 1.55 | 1.07 |
Current Unearned Revenue | - | 0.4 | 1.66 | 1.28 | 9.79 |
Other Current Liabilities | 3.78 | 4.82 | 1.23 | 0.66 | 0.63 |
Total Current Liabilities | 9.52 | 12.63 | 19.6 | 14.47 | 18.25 |
Long-Term Leases | 25.44 | 30.26 | 21.45 | 0.67 | 0.38 |
Long-Term Unearned Revenue | 11.86 | 11.86 | 12.14 | 14.08 | 1.93 |
Total Liabilities | 46.83 | 54.75 | 53.18 | 29.21 | 20.55 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0.06 | 0.03 | 0.01 |
Additional Paid-In Capital | 422.99 | 416.38 | 400.69 | 329.39 | 227.7 |
Retained Earnings | -433.71 | -404.79 | -311.36 | -248.68 | -193.4 |
Comprehensive Income & Other | - | - | 0.03 | 0.01 | - |
Total Common Equity | -10.72 | 11.59 | 89.42 | 80.75 | 34.32 |
Shareholders' Equity | -10.72 | 11.59 | 89.42 | 80.75 | 34.32 |
Total Liabilities & Equity | 36.11 | 66.35 | 142.6 | 109.97 | 54.87 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 30.26 | 34.38 | 26.88 | 2.22 | 1.45 |
Net Cash (Debt) | -14.37 | 6.2 | 75.87 | 95.68 | 44.29 |
Net Cash Growth | - | -91.83% | -20.70% | 116.01% | -38.61% |
Net Cash Per Share | -9.25 | 4.76 | 76.17 | 158.22 | 170.54 |
Filing Date Shares Outstanding | 1.77 | 1.32 | 1.19 | 0.64 | 0.26 |
Total Common Shares Outstanding | 1.77 | 1.31 | 1.14 | 0.64 | 0.26 |
Working Capital | 6.75 | 30.39 | 85.22 | 86.36 | 29.67 |
Book Value Per Share | -6.04 | 8.85 | 78.14 | 126.86 | 131.91 |
Tangible Book Value | -10.72 | 11.59 | 89.42 | 80.75 | 34.32 |
Tangible Book Value Per Share | -6.04 | 8.85 | 78.14 | 126.86 | 131.91 |
Machinery | 4.89 | 4.89 | 3.4 | 5.35 | 5.59 |
Leasehold Improvements | 0.55 | 0.49 | 0.46 | 0.4 | 2.11 |